- Home
- OPY vs ERAS Comparison
OPY vs ERAS Comparison
Compare OPY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- ERAS
- Stock Information
- Founded
- OPY 1881
- ERAS 2018
- Country
- OPY United States
- ERAS United States
- Employees
- OPY N/A
- ERAS N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- OPY Finance
- ERAS Health Care
- Exchange
- OPY Nasdaq
- ERAS Nasdaq
- Market Cap
- OPY 666.7M
- ERAS 723.8M
- IPO Year
- OPY N/A
- ERAS 2021
- Fundamental
- Price
- OPY $63.44
- ERAS $1.93
- Analyst Decision
- OPY
- ERAS Strong Buy
- Analyst Count
- OPY 0
- ERAS 5
- Target Price
- OPY N/A
- ERAS $5.70
- AVG Volume (30 Days)
- OPY 22.5K
- ERAS 1.3M
- Earning Date
- OPY 01-24-2025
- ERAS 11-12-2024
- Dividend Yield
- OPY 1.15%
- ERAS N/A
- EPS Growth
- OPY 83.00
- ERAS N/A
- EPS
- OPY 6.42
- ERAS N/A
- Revenue
- OPY $1,280,442,000.00
- ERAS N/A
- Revenue This Year
- OPY N/A
- ERAS N/A
- Revenue Next Year
- OPY N/A
- ERAS N/A
- P/E Ratio
- OPY $9.82
- ERAS N/A
- Revenue Growth
- OPY 7.32
- ERAS N/A
- 52 Week Low
- OPY $36.93
- ERAS $1.64
- 52 Week High
- OPY $70.25
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- OPY 51.98
- ERAS 28.40
- Support Level
- OPY $61.76
- ERAS $2.65
- Resistance Level
- OPY $65.70
- ERAS $2.84
- Average True Range (ATR)
- OPY 1.54
- ERAS 0.18
- MACD
- OPY -0.28
- ERAS -0.05
- Stochastic Oscillator
- OPY 42.52
- ERAS 4.69
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has three segments: private client, asset management, and capital markets. The Private Client segment, commissions and a proportionate amount of fee income earned on assets under management ("AUM"), net interest earnings on client margin loans and cash balances, fees from money market funds, and custodian fees. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.